RxDoctor Payments Data

Chad Olinger, DO

Cardiovascular Disease · Coon Rapids, MNNPI 1144325366

Payments from drug & device makers

$161,768in general payments, 2019–2025

Across 112 payments — averaging $1444.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lantheus Medical Imaging, Inc.$128K
  • Boston Scientific$19K
  • Philips North America LLC$10K
  • Abbott$3K
  • Heartflow, Inc.$579
  • Medtronic$289
  • plus $554 from 10 others
$1,425in research payments, 2019–2025

Across 1 payment — averaging $1425.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Philips North America LLC$1K

What the payments were for

  • Consulting fees$10,02526%
  • Speaking & faculty fees$19,55050%
  • Travel & lodging$5,51514%
  • Food & beverage$3,6509%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$161,768 in reported general payments places this provider in the 85th percentile of 451 cardiovascular disease providers in Minnesota.

See all cardiovascular disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$49,107
Medicare patients
486
Services billed
875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$86,292
XareltoRivaroxaban43$43,299
EntrestoSacubitril/Valsartan13$24,164
BrilintaTicagrelor23$18,166
Bumetanide45$2,269
Metoprolol Succinate105$2,003
Potassium Chloride42$1,903
Atorvastatin Calcium80$1,600
Diltiazem 24hr Er (Cd)Diltiazem Hcl29$849
Rosuvastatin Calcium65$809
ClopidogrelClopidogrel Bisulfate45$773
Amiodarone Hcl37$675
Isosorbide Mononitrate ErIsosorbide Mononitrate31$670
Losartan Potassium55$664
Carvedilol64$563

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$86,29269 claims
NovartisEntresto$16$24,16413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 451 cardiovascular disease providers in Minnesota.

Other cardiovascular disease in Coon Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →